The Virtual Consulting Firm – TheVCF.com

Let Us Help You Market, Manage, and Grow! Your Business Today!

Swing Trade Stock Picks

Home Forums Stocks Swing Trading Swing Trade Stock Picks

This topic contains 55 replies, has 1 voice, and was last updated by  Michael DeVries 3 days, 21 hours ago.

Viewing 25 posts - 26 through 50 (of 56 total)
  • Author
    Posts
  • #2489

    Michael DeVries
    Keymaster

    The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 07/24/2017 – 07/28/2017:

    1) ATEC – Alphatec Holdings Inc – Trading Below Cash
    a. Buy at < ~ $1.62
    b. Sell at >~ $5.80

    2) CYCC – Cyclacel Pharmaceuticals Inc – Trading Below Cash
    a. Buy at < ~ $1.72
    b. Sell at >~ $3.00
    c. Catalysts:
    1. Phase 1 – A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors; 20180701; 20180731; https://ClinicalTrials.gov/show/NCT00999401
    2. A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors; 20180701; 20180731; https://www.clinicaltrials.gov/ct2/show/NCT00999401?term=Cyclacel&recr=Open&rank=2
    3. Phase 2 – Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation; 20170801; 20171031; https://ClinicalTrials.gov/show/NCT02649751
    4. Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23) Phase 2; 20190701; 20190731; https://www.clinicaltrials.gov/ct2/show/NCT01253460?term=Cyclacel&rank=11
    5. Phase 2 – Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23); 20190701; 20190731; https://ClinicalTrials.gov/show/NCT01253460
    6. Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation (ROSCO-CF); 20180801; 20181031; https://www.clinicaltrials.gov/ct2/show/NCT02649751?term=Cyclacel&recr=Open&rank=3

    3) UNXL – Uni-Pixel Inc
    a. Buy at < ~ $0.35
    b. Sell at >~ $0.60

    4) EGLT – Egalet Corp – Trading Below Cash
    a. Buy at < ~ $1.32
    b. Sell at >~ $2.00
    c. Catalysts:
    1. Phase 3 to be completed 4Q 2017. NDA planned for 2018. – Egalet-002 – Moderate to severe chronic pain – Phase 3; 20171001; 20171231; http://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=11315453&type=HTML&symbol=EGLT&companyName=Egalet+Corporation&formType=8-K&dateFiled=2017-01-09

    5) GALE – Galena Biopharma Inc – Trading Below Cash
    a. Buy at < ~ $0.53
    b. Sell at >~ $0.79
    c. Catalysts:
    1. NeuVax™ + trastuzumab, HER2 1+,2+ Phase 2b DSMB expects to perform the interim efficacy analysis near the end of 2017; 20171115; 20171231; https://www.galenabiopharma.com/pipeline/neuvax-nelipepimut-s/neuvax-trastuzumab-her2-1-2/default.aspx
    2. Q2 2017 Galena Biopharma Inc Earnings Release (Estimated)
    -; 20170807; 20170807; https://www.google.com/finance?q=GALE
    3. Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients (HER3+); 20191231; 20201231; https://clinicaltrials.gov/ct2/show/NCT02297698?term=neuvax&rank=1
    4. Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer; 20190301; 20190331; https://clinicaltrials.gov/ct2/show/NCT02636582?term=NCT02636582&rank=1

    6) ANTH – Anthera Pharmaceuticals Inc – Trading Below Cash
    a. Buy at < ~ $1.47
    b. Sell at >~ $2.05
    c. Catalysts:
    1. Phase 4 – EASY: Extended Access to Sollpura Over Years; 20170901; 20171231; https://ClinicalTrials.gov/show/NCT02823964
    2. Phase 2 primary endpoint not met following interim analysis. Trial to continue. Data due 3Q 2017. – Blisibimod – IgA nephropathy – Phase 2; 20170630; 20170930; http://investor.anthera.com/releasedetail.cfm?ReleaseID=1025900
    3. Phase 3 – BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy; 20161001; 20211031; https://ClinicalTrials.gov/show/NCT02052219
    4. Phase 3 – CHABLIS-SC2: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis; 20180601; 20180630; https://ClinicalTrials.gov/show/NCT02074020
    5. Phase 3 data due end of 2017 or early 2018. – Sollpura – RESULT – Exocrine pancreatic insufficiency – Phase 3; 20180331; 20180331; http://files.shareholder.com/downloads/ABEA-3R5RJ7/2039745217x0x948640/5EE14DFC-C765-43AD-B65D-BC5471C38EB7/ANTH_News_2017_7_6_General_Releases.pdf
    6. Phase 3 – RESULT: Reliable, Emergent Solution Using Liprotamase Treatment; 20171101; 20171231; https://ClinicalTrials.gov/show/NCT03051490

    7) TISA – Top Image Systems Ltd.
    a. Buy at < ~ $1.11
    b. Sell at >~ $2.45

    8) AGTC – Applied Genetic Technologies Corp – Trading Below Cash
    a. Buy at < ~ $4.60
    b. Sell at >~ $6.05
    c. Catalysts:
    1. Phase 1Phase 2 – Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS); 20171201; 20201231; https://ClinicalTrials.gov/show/NCT02416622
    2. Phase 1Phase 2 – Phase 1/2 Safety and Efficacy Study of AAV-RPE65 Vector to Treat Leber Congenital Amaurosis; 20140901; 20271231; https://ClinicalTrials.gov/show/NCT00749957
    3. Phase 1Phase 2 – Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia; 20190601; 20230630; https://ClinicalTrials.gov/show/NCT02935517
    4. Phase 1Phase 2 – Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGB3 Achromatopsia; 20181201; 20221231; https://ClinicalTrials.gov/show/NCT02599922

    What do you think about these Stock Picks to Buy at these Price Targets?

    What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 07/24/2017 – 07/28/2017, and Why?

    #2491

    Michael DeVries
    Keymaster

    #Bullish #Stocks currently #TradingBelowCash (#TBC) as of 07/21/2017 include:

    1. $ADHD – Alcobra Ltd :
      1. Cash/sh = $1.81
    2. $AVIR – Aviragen Therapeutics Inc :
      1. Cash/sh = $0.97
    3. $DMTX – Dimension Therapeutics Inc :
      1. Cash/sh = $2.36
    4. $EARS – Auris Medical Holding AG :
      1. Cash/sh = $1.12
    5. $ECYT – Endocyte, Inc. :
      1. Cash/sh = $2.91
    6. $OPHT – Ophthotech Corp :
      1. Cash/sh = $6.30
    7. $OREX – Orexigen Therapeutics, Inc. :
      1. Cash/sh = $5.82
    8. $ROKA – Roka Bioscience Inc :
      1. Cash/sh = $3.19
    9. $TNDM – Tandem Diabetes Care Inc :
      1. Cash/sh = $0.92

    Please also Share Your Favorite Stocks currently Trading Below Cash (TBC) here in this Topic as well, ok?

    #2492

    Michael DeVries
    Keymaster

    #Bullish #Stocks currently #TradingBelowBook ( #TBB ) as of 07/21/2017 include:

    1. $ADHD – Alcobra Ltd :
      1. Book/sh = $1.71
    2. $AVIR – Aviragen Therapeutics Inc :
      1. Book/sh = $0.63
    3. $DMTX – Dimension Therapeutics Inc :
      1. Book/sh = $1.90
    4. $ECYT – Endocyte, Inc. :
      1. Book/sh = $2.99
    5. $LBIX – Leading Brands, Inc (USA) :
      1. Book/sh = $1.81
    6. $ROKA – Roka Bioscience Inc :
      1. Book/sh = $5.93
    7. $TNXP – Tonix Pharmaceuticals Holding Corp. :
      1. Book/sh = $5.51

    Please also Share Your Favorite Stocks currently Trading Below Book (TBB) here in this Topic as well, ok?

    #2500

    Michael DeVries
    Keymaster

    The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 07/31/2017 – 08/04/2017:

    1) ATEC – Alphatec Holdings Inc – Trading Below Cash
    a. Buy at < ~ $1.58
    b. Sell at >~ $5.80

    2) CYCC – Cyclacel Pharmaceuticals Inc – Trading Below Cash
    a. Buy at < ~ $1.71
    b. Sell at >~ $3.00
    c. Catalysts:
    1. Phase 1 – A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors; 20180701; 20180731; https://ClinicalTrials.gov/show/NCT00999401
    2. A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors; 20180701; 20180731; https://www.clinicaltrials.gov/ct2/show/NCT00999401?term=Cyclacel&recr=Open&rank=2
    3. Phase 2 – Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation; 20170801; 20171031; https://ClinicalTrials.gov/show/NCT02649751
    4. Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23) Phase 2; 20190701; 20190731; https://www.clinicaltrials.gov/ct2/show/NCT01253460?term=Cyclacel&rank=11
    5. Phase 2 – Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23); 20190701; 20190731; https://ClinicalTrials.gov/show/NCT01253460
    6. Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation (ROSCO-CF); 20180801; 20181031; https://www.clinicaltrials.gov/ct2/show/NCT02649751?term=Cyclacel&recr=Open&rank=3

    3) EGLT – Egalet Corp – Trading Below Cash
    a. Buy at < ~ $1.32
    b. Sell at >~ $2.00
    c. Catalysts:
    1. Phase 3 to be completed 4Q 2017. NDA planned for 2018. – Egalet-002 – Moderate to severe chronic pain – Phase 3; 20171001; 20171231; http://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=11315453&type=HTML&symbol=EGLT&companyName=Egalet+Corporation&formType=8-K&dateFiled=2017-01-09

    4) GALE – Galena Biopharma Inc – Trading Below Cash
    a. Buy at < ~ $0.53
    b. Sell at >~ $0.79
    c. Catalysts:
    1. Phase 2b enrollment due to be completed in a few weeks (noted July 12, 2017) with interim efficacy analysis due 6 months following – i.e. likely 1Q 2018. – NeuVax in combination with Herceptin – Breast cancer – Phase 2b; 20180331; 20180331; https://investors.galenabiopharma.com/investors/press-releases/press-release-details/2017/Galena-Biopharma-Provides-Corporate-Update/default.aspx
    2. NeuVax™ + trastuzumab, HER2 1+,2+ Phase 2b DSMB expects to perform the interim efficacy analysis near the end of 2017; 20171115; 20171231; https://www.galenabiopharma.com/pipeline/neuvax-nelipepimut-s/neuvax-trastuzumab-her2-1-2/default.aspx
    3. Q2 2017 Galena Biopharma Inc Earnings Release (Estimated)
    -; 20170807; 20170807; https://www.google.com/finance?q=GALE
    4. Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer; 20190301; 20190331; https://clinicaltrials.gov/ct2/show/NCT02636582?term=NCT02636582&rank=1
    5. Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients (HER3+); 20191231; 20201231; https://clinicaltrials.gov/ct2/show/NCT02297698?term=neuvax&rank=1
    6. Phase 2 – Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients; 20191201; 20201231; https://ClinicalTrials.gov/show/NCT02297698
    7. Phase 2 – Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax; 20190601; 20200630; https://ClinicalTrials.gov/show/NCT01570036

    5) ANTH – Anthera Pharmaceuticals Inc – Trading Below Cash
    a. Buy at < ~ $1.38
    b. Sell at >~ $2.05
    c. Catalysts:
    1. Phase 4 – EASY: Extended Access to Sollpura Over Years; 20170901; 20171231; https://ClinicalTrials.gov/show/NCT02823964
    2. Phase 2 primary endpoint not met following interim analysis. Trial to continue. Data due 3Q 2017. – Blisibimod – IgA nephropathy – Phase 2; 20170630; 20170930; http://investor.anthera.com/releasedetail.cfm?ReleaseID=1025900
    3. Phase 3 – BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy; 20161001; 20211031; https://ClinicalTrials.gov/show/NCT02052219
    4. Phase 3 – CHABLIS-SC2: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis; 20180601; 20180630; https://ClinicalTrials.gov/show/NCT02074020
    5. Phase 3 data due end of 2017 or early 2018. – Sollpura – RESULT – Exocrine pancreatic insufficiency – Phase 3; 20180331; 20180331; http://files.shareholder.com/downloads/ABEA-3R5RJ7/2039745217x0x948640/5EE14DFC-C765-43AD-B65D-BC5471C38EB7/ANTH_News_2017_7_6_General_Releases.pdf
    6. Phase 3 – RESULT: Reliable, Emergent Solution Using Liprotamase Treatment; 20171101; 20171231; https://ClinicalTrials.gov/show/NCT03051490

    6) TISA – Top Image Systems Ltd.
    a. Buy at < ~ $1.11
    b. Sell at >~ $2.45

    7) AGTC – Applied Genetic Technologies Corp – Trading Below Cash
    a. Buy at < ~ $4.60
    b. Sell at >~ $6.05
    c. Catalysts:
    1. Phase 1Phase 2 – Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS); 20171201; 20201231; https://ClinicalTrials.gov/show/NCT02416622
    2. Phase 1Phase 2 – Phase 1/2 Safety and Efficacy Study of AAV-RPE65 Vector to Treat Leber Congenital Amaurosis; 20140901; 20271231; https://ClinicalTrials.gov/show/NCT00749957
    3. Phase 1Phase 2 – Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia; 20190601; 20230630; https://ClinicalTrials.gov/show/NCT02935517
    4. Phase 1Phase 2 – Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGB3 Achromatopsia; 20181201; 20221231; https://ClinicalTrials.gov/show/NCT02599922

    8) AGLE – Aeglea Bio Therapeutics Inc – Trading Below Cash
    a. Buy at < ~ $3.26
    b. Sell at >~ $4.00

    What do you think about these Stock Picks to Buy at these Price Targets?

    What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 07/31/2017 – 08/04/2017, and Why?

    #2501

    Michael DeVries
    Keymaster

    Bullish Stocks currently Trading Below Cash (TBC) as of 07/28/2017 include:

    1. $ADHD – Alcobra Ltd :
      1. Cash/sh = $1.81
    2. $AVIR – Aviragen Therapeutics Inc :
      1. Cash/sh = $0.97
    3. $DMTX – Dimension Therapeutics Inc :
      1. Cash/sh = $2.36
    4. $EARS – Auris Medical Holding AG :
      1. Cash/sh = $1.12
    5. $ECYT – Endocyte, Inc. :
      1. Cash/sh = $2.91
    6. $OPHT – Ophthotech Corp :
      1. Cash/sh = $6.30
    7. $ROKA – Roka Bioscience Inc :
      1. Cash/sh = $3.19
    8. $TNDM – Tandem Diabetes Care Inc :
      1. Cash/sh = $0.92

    Please also Share Your Favorite Stocks currently Trading Below Cash (TBC) here in this Topic as well, ok?

    #2502

    Michael DeVries
    Keymaster

    #Bullish #Stocks currently #TradingBelowBook (#TBB ) as of 07/28/2017 include:

    1. $ADHD – Alcobra Ltd :
      1. Book/sh = $1.71
    2. $AVIR – Aviragen Therapeutics Inc :
      1. Book/sh = $0.63
    3. $DMTX – Dimension Therapeutics Inc :
      1. Book/sh = $1.90
    4. $ECYT – Endocyte, Inc. :
      1. Book/sh = $2.99
    5. $LBIX – Leading Brands, Inc (USA) :
      1. Book/sh = $1.81
    6. $ROKA – Roka Bioscience Inc :
      1. Book/sh = $5.93
    7. $TNXP – Tonix Pharmaceuticals Holding Corp. :
      1. Book/sh = $5.51

    Please also Share Your Favorite Stocks currently Trading Below Book (TBB) here in this Topic as well, ok?

    #2507

    Michael DeVries
    Keymaster

    The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 08/07/2017 – 08/11/2017:

    1) ATEC – Alphatec Holdings Inc – Trading Below Cash
    a. Buy at < ~ $1.58
    b. Sell at >~ $5.80

    2) HEB – Hemispherx BioPharma, Inc
    a. Buy at < ~ $0.40
    b. Sell at >~ $0.75
    c. Catalysts:
    1. Phase 1Phase 2 – Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines; 20170701; 20201231; https://ClinicalTrials.gov/show/NCT02432378
    2. Phase 1Phase 2 – Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer; 20171201; 20181231; https://ClinicalTrials.gov/show/NCT01545141
    3. Phase 3 – Ampligen in Chronic Fatigue Syndrome; 20190201; 20190228; https://ClinicalTrials.gov/show/NCT00215813

    3) GALE – Galena Biopharma Inc – Trading Below Cash
    a. Buy at < ~ $0.53
    b. Sell at >~ $0.79
    c. Catalysts:
    1. Phase 2b enrollment due to be completed in a few weeks (noted July 12, 2017) with interim efficacy analysis due 6 months following – i.e. likely 1Q 2018. – NeuVax in combination with Herceptin – Breast cancer – Phase 2b; 20180331; 20180331; https://investors.galenabiopharma.com/investors/press-releases/press-release-details/2017/Galena-Biopharma-Provides-Corporate-Update/default.aspx
    2. NeuVax™ + trastuzumab, HER2 1+,2+ Phase 2b DSMB expects to perform the interim efficacy analysis near the end of 2017; 20171115; 20171231; https://www.galenabiopharma.com/pipeline/neuvax-nelipepimut-s/neuvax-trastuzumab-her2-1-2/default.aspx
    3. Q2 2017 Galena Biopharma Inc Earnings Release (Estimated)
    -; 20170807; 20170807; https://www.google.com/finance?q=GALE
    4. Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer; 20190301; 20190331; https://clinicaltrials.gov/ct2/show/NCT02636582?term=NCT02636582&rank=1
    5. Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients (HER3+); 20191231; 20201231; https://clinicaltrials.gov/ct2/show/NCT02297698?term=neuvax&rank=1
    6. Phase 2 – Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients; 20191201; 20201231; https://ClinicalTrials.gov/show/NCT02297698
    7. Phase 2 – Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax; 20190601; 20200630; https://ClinicalTrials.gov/show/NCT01570036

    4) AGTC – Applied Genetic Technologies Corp – Trading Below Cash
    a. Buy at < ~ $4.50
    b. Sell at >~ $6.05
    c. Catalysts:
    1. Phase 1Phase 2 – Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS); 20171201; 20201231; https://ClinicalTrials.gov/show/NCT02416622
    2. Phase 1Phase 2 – Phase 1/2 Safety and Efficacy Study of AAV-RPE65 Vector to Treat Leber Congenital Amaurosis; 20140901; 20271231; https://ClinicalTrials.gov/show/NCT00749957
    3. Phase 1Phase 2 – Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia; 20190601; 20230630; https://ClinicalTrials.gov/show/NCT02935517
    4. Phase 1Phase 2 – Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGB3 Achromatopsia; 20181201; 20221231; https://ClinicalTrials.gov/show/NCT02599922

    5) AGLE – Aeglea Bio Therapeutics Inc – Trading Below Cash
    a. Buy at < ~ $3.11
    b. Sell at >~ $4.00

    What do you think about these Stock Picks to Buy at these Price Targets?

    What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 08/07/2017 – 08/11/2017, and Why?

    #2508

    Michael DeVries
    Keymaster

    Bullish Stocks currently Trading Below Cash (TBC) as of 08/04/2017 include:

    1. $ADHD – Alcobra Ltd :
      1. Cash/sh = $1.81
    2. $ANTH – Anthera Pharmaceuticals Inc :
      1. Cash/sh = $1.97
    3. $AVIR – Aviragen Therapeutics Inc :
      1. Cash/sh = $0.97
    4. $CYCC – Cyclacel Pharmaceuticals Inc :
      1. Cash/sh = $1.93
    5. $DMTX – Dimension Therapeutics Inc :
      1. Cash/sh = $2.36
    6. $EARS – Auris Medical Holding AG :
      1. Cash/sh = $1.12
    7. $ECYT – Endocyte, Inc. :
      1. Cash/sh = $2.91
    8. $EGLT – Egalet Corp :
      1. Cash/sh = $2.30
    9. $OPHT – Ophthotech Corp :
      1. Cash/sh = $6.30
    10. $ROKA – Roka Bioscience Inc :
      1. Cash/sh = $3.19
    11. $TNDM – Tandem Diabetes Care Inc :
      1. Cash/sh = $0.92

    Please also Share Your Favorite Stocks currently Trading Below Cash (TBC) here in this Topic as well, ok?

    #2510

    Michael DeVries
    Keymaster

    #Bullish #Stocks currently #TradingBelowBook (#TBB ) as of 08/04/2017 include:

    1. $ADHD – Alcobra Ltd :
      1. Book/sh = $1.71
    2. $AVIR – Aviragen Therapeutics Inc :
      1. Book/sh = $0.63
    3. $CYCC – Cyclacel Pharmaceuticals Inc :
      1. Book/sh = $3.00
    4. $DMTX – Dimension Therapeutics Inc :
      1. Book/sh = $1.90
    5. $ECYT – Endocyte, Inc. :
      1. Book/sh = $2.99
    6. $ROKA – Roka Bioscience Inc :
      1. Book/sh = $5.93
    7. $TNXP – Tonix Pharmaceuticals Holding Corp. :
      1. Book/sh = $5.51

    Please also Share Your Favorite Stocks currently Trading Below Book (TBB) here in this Topic as well, ok?

    #2519

    Michael DeVries
    Keymaster

    The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 08/14/2017 – 08/18/2017:

    1) ATEC – Alphatec Holdings Inc – Trading Below Cash
    a. Buy at < ~ $1.58
    b. Sell at >~ $5.80

    2) HEB – Hemispherx BioPharma, Inc
    a. Buy at < ~ $0.36
    b. Sell at >~ $0.75
    c. Catalysts:
    1. Phase 1Phase 2 – Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines; 20170701; 20201231; https://ClinicalTrials.gov/show/NCT02432378
    2. Phase 1Phase 2 – Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer; 20171201; 20181231; https://ClinicalTrials.gov/show/NCT01545141
    3. Phase 3 – Ampligen in Chronic Fatigue Syndrome; 20190201; 20190228; https://ClinicalTrials.gov/show/NCT00215813

    3) ONCS – OncoSec Medical Inc
    a. Buy at < ~ $0.88
    b. Sell at >~ $1.30
    c. Catalysts:
    1. Phase 2 enrollment to commence June 2017 with data due 4Q 2017. – ImmunoPulse IL-12 – Melanoma – cancer – Phase 2; 20171001; 20171231; http://ir.oncosec.com/press-releases/detail/1907
    2. Phase 2Phase 3 – pIL-12 and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Pembrolizumab or Nivolumab Treatment; 20180901; 20191201; https://ClinicalTrials.gov/show/NCT03132675

    4) AGLE – Aeglea Bio Therapeutics Inc – Trading Below Cash
    a. Buy at < ~ $2.81
    b. Sell at >~ $4.00

    5) SCYX – SCYNEXIS Inc – Trading Below Cash
    a. Buy at < ~ $1.52
    b. Sell at >~ $2.00
    c. Catalysts:
    1. Mid-2017 – Submission of IV data analysis to FDA; 20170601; 20171231; https://twitter.com/crewdog58/status/871138614591270912
    2. Open-Label Study to Evaluate Efficacy and Safety of SCY-078 in Patients With Refractory or Intolerant Fungal Diseases (FURI); 20190901; 20191231; https://clinicaltrials.gov/ct2/show/NCT03059992?term=SCYNEXIS&rank=3

    What do you think about these Stock Picks to Buy at these Price Targets?

    What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 08/14/2017 – 08/18/2017, and Why?

    #2522

    Michael DeVries
    Keymaster

    Bullish Stocks currently Trading Below Cash (TBC) as of 08/18/2017 include:

    1. $ADHD – Alcobra Ltd :
      1. Cash/sh = $1.81
    2. $ANTH – Anthera Pharmaceuticals Inc :
      1. Cash/sh = $1.97
    3. $AVIR – Aviragen Therapeutics Inc :
      1. Cash/sh = $0.95
    4. $CYCC – Cyclacel Pharmaceuticals Inc :
      1. Cash/sh = $1.93
    5. $DMTX – Dimension Therapeutics Inc :
      1. Cash/sh = $2.36
    6. $EARS – Auris Medical Holding AG :
      1. Cash/sh = $1.12
    7. $ECYT – Endocyte, Inc. :
      1. Cash/sh = $2.85
    8. $EGLT – Egalet Corp :
      1. Cash/sh = $2.30
    9. $OPHT – Ophthotech Corp :
      1. Cash/sh = $5.44
    10. $ROKA – Roka Bioscience Inc :
      1. Cash/sh = $3.19
    11. $TNXP – Tonix Pharmaceuticals Holding Corp. :
      1. Cash/sh = $3.04

    Please also Share Your Favorite Stocks currently Trading Below Cash (TBC) here in this Topic as well, ok?

    #2523

    Michael DeVries
    Keymaster

    #Bullish #Stocks currently #TradingBelowBook (#TBB ) as of 08/18/2017 include:

    1. $ADHD – Alcobra Ltd :
      1. Book/sh = $1.71
    2. $AVIR – Aviragen Therapeutics Inc :
      1. Book/sh = $0.63
    3. $CYCC – Cyclacel Pharmaceuticals Inc :
      1. Book/sh = $3.00
    4. $DMTX – Dimension Therapeutics Inc :
      1. Book/sh = $1.90
    5. $ECYT – Endocyte, Inc. :
      1. Book/sh = $2.73
    6. $KTOV – Kitov Pharmaceuticals Holdings Ltd :
      1. Book/sh = $1.80
    7. $LBIX – Leading Brands, Inc (USA) :
      1. Book/sh = $1.19
    8. $NVGN – Novogen Limited (ADR) :
      1. Book/sh = $22.22
    9. $ROKA – Roka Bioscience Inc :
      1. Book/sh = $5.93
    10. $TNXP – Tonix Pharmaceuticals Holding Corp. :
      1. Book/sh = $5.51

    Please also Share Your Favorite Stocks currently Trading Below Book (TBB) here in this Topic as well, ok?

    #2526

    Michael DeVries
    Keymaster

    The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 08/28/2017 – 09/01/2017:

    1) HEB – Hemispherx BioPharma, Inc
    a. Buy at < ~ $0.36
    b. Sell at >~ $0.75
    c. Catalysts:
    1. Phase 1Phase 2 – Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines; 20170701; 20201231; https://ClinicalTrials.gov/show/NCT02432378
    2. Phase 1Phase 2 – Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer; 20171201; 20181231; https://ClinicalTrials.gov/show/NCT01545141
    3. Phase 3 – Ampligen in Chronic Fatigue Syndrome; 20190201; 20190228; https://ClinicalTrials.gov/show/NCT00215813

    2) ONCS – OncoSec Medical Inc
    a. Buy at < ~ $0.88
    b. Sell at >~ $1.30
    c. Catalysts:
    1. Phase 2 enrollment to commence June 2017 with data due 4Q 2017. – ImmunoPulse IL-12 – Melanoma – cancer – Phase 2; 20171001; 20171231; http://ir.oncosec.com/press-releases/detail/1907
    2. Q4 2017 OncoSec Medical Inc Earnings Release (Estimated)
    -; 20171011; 20171011; https://www.google.com/finance?q=ONCS
    3. Phase 2Phase 3 – pIL-12 and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Pembrolizumab or Nivolumab Treatment; 20180901; 20191201; https://ClinicalTrials.gov/show/NCT03132675

    3) TISA – Top Image Systems Ltd.
    a. Buy at < ~ $1.10
    b. Sell at >~ $1.38

    4) TRIL – Trillium Therapeutics Inc.
    a. Buy at < ~ $4.15
    b. Sell at >~ $4.95
    c. Catalysts:
    1. Phase 2 – Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer; 20170930; 20170930; https://ClinicalTrials.gov/show/NCT01010126
    2. NA – A Canadian Observational Study in Metastatic Cancer of the Prostate: A Study of ZYTIGA Use in the Community Urology Setting; 20170815; 20181030; https://ClinicalTrials.gov/show/NCT02364531
    3. Phase 3 – Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery; 20180101; 20180131; https://ClinicalTrials.gov/show/NCT00324805
    4. Phase 3 – Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial); 20171231; 20171231; https://ClinicalTrials.gov/show/NCT00310180
    5. Phase 1Phase 2 – Thoracic Surgery Extended Low-Molecular Weight Heparin VTE Prophylaxis–Pilot Trial; 20170601; 20170831; https://ClinicalTrials.gov/show/NCT02334007
    6. Phase 3 – Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer; 20140601; 20200630; https://ClinicalTrials.gov/show/NCT00066703
    7. Phase 3 – A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer; 20110513; 20220312; https://ClinicalTrials.gov/show/NCT00567190
    8. Phase 4 – Diabetes Care Management Compared to Standard Diabetes Care in Adolescents and Young Adults With Type 1 Diabetes; 20170501; 20171031; https://ClinicalTrials.gov/show/NCT01351857
    9. Phase 3 – Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer; 20150201; 20171231; https://ClinicalTrials.gov/show/NCT00265850
    10. Phase 3 – Lifestyle Intervention Study in Adjuvant Treatment of Early Breast Cancer; 20180501; 20180531; https://ClinicalTrials.gov/show/NCT00463489
    11. Phase 3 – A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer; 20200101; 20200731; https://ClinicalTrials.gov/show/NCT01101438
    12. NA – Womens Initiative Supporting Health Increasing Healthcare Access; 20190601; 20190731; https://ClinicalTrials.gov/show/NCT02964845
    13. Phase 3 – Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer; 20220201; 20220228; https://ClinicalTrials.gov/show/NCT01272037
    14. Phase 3 – High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery; 20200601; 20200601; https://ClinicalTrials.gov/show/NCT02506153
    15. Phase 1 – A Trial of TTI-621 for Patients With Hematologic Malignancies and Selected Solid Tumors; 20190601; 20190630; https://ClinicalTrials.gov/show/NCT02663518
    16. Phase 1 – Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides; 20181201; 20191231; https://ClinicalTrials.gov/show/NCT02890368
    17. Phase 3 – Effect of MD1003 in Progressive Multiple Sclerosis (SPI2); 20180901; 20190930; https://ClinicalTrials.gov/show/NCT02936037
    18. Phase 3 – Field Randomization of NA-1 Therapy in Early Responders; 20190301; 20190531; https://ClinicalTrials.gov/show/NCT02315443
    19. Phase 3 – FIBrinogen REplenishment in Surgery; 20190130; 20190330; https://ClinicalTrials.gov/show/NCT03037424

    What do you think about these Stock Picks to Buy at these Price Targets?

    What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 08/28/2017 – 09/01/2017, and Why?

    #2544

    Michael DeVries
    Keymaster

    The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 09/05/2017 – 09/08/2017:

    1) OTIC – Otonomy Inc – Trading Below Cash
    a. Buy at < ~ $3.30
    b. Sell at >~ $10.50
    c. Catalysts:
    1. Phase 3 – Study of OTO-104 in Subjects With Unilateral Menieres Disease; 20171101; 20171130; https://ClinicalTrials.gov/show/NCT02717442
    2. Q3 2017 Otonomy Inc Earnings Release (Estimated)
    -; 20171101; 20171101; https://www.google.com/finance?q=OTIC
    3. Phase 2 – Open Label Study of OTO-104 in Subjects With Menieres Disease; 20171001; 20171031; https://ClinicalTrials.gov/show/NCT02740387
    4. Phase 3 trial met primary endpoint – January 5, 2017. PDUFA date for sNDA filing March 2, 2018. – OTIPRIO – Acute otitis externa – Phase 3; 20180302; 20180302; http://investors.otonomy.com/phoenix.zhtml?c=234082&p=irol-newsArticle_Print&ID=2286970
    5. Phase 2 – Study of OTO-104 in Subjects at Risk From Cisplatin-Induced Hearing Loss; 20180301; 20180630; https://ClinicalTrials.gov/show/NCT02997189
    6. Phase 3 – A 6-Month Extension Study of OTO-104 in Menieres Disease; 20180101; 20180131; https://ClinicalTrials.gov/show/NCT02706730

    2) HEB – Hemispherx BioPharma, Inc
    a. Buy at < ~ $0.36
    b. Sell at >~ $0.75
    c. Catalysts:
    1. Phase 1Phase 2 – Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines; 20170701; 20201231; https://ClinicalTrials.gov/show/NCT02432378
    2. Phase 1Phase 2 – Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer; 20171201; 20181231; https://ClinicalTrials.gov/show/NCT01545141
    3. Phase 3 – Ampligen in Chronic Fatigue Syndrome; 20190201; 20190228; https://ClinicalTrials.gov/show/NCT00215813

    3) ONCS – OncoSec Medical Inc
    a. Buy at < ~ $0.88
    b. Sell at >~ $1.30
    c. Catalysts:
    1. Phase 2 enrollment to commence June 2017 with data due 4Q 2017. – ImmunoPulse IL-12 – Melanoma – cancer – Phase 2; 20171001; 20171231; http://ir.oncosec.com/press-releases/detail/1907
    2. Q4 2017 OncoSec Medical Inc Earnings Release (Estimated)
    -; 20171011; 20171011; https://www.google.com/finance?q=ONCS
    3. Phase 2Phase 3 – pIL-12 and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Pembrolizumab or Nivolumab Treatment; 20180901; 20191201; https://ClinicalTrials.gov/show/NCT03132675

    4) TISA – Top Image Systems Ltd.
    a. Buy at < ~ $1.10
    b. Sell at >~ $1.38

    What do you think about these Stock Picks to Buy at these Price Targets?

    What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 09/05/2017 – 09/08/2017, and Why?

    #2547

    Michael DeVries
    Keymaster

    Bullish Stocks currently Trading Below Cash (TBC) as of 09/01/2017 include:

    1. $ADHD – Alcobra Ltd :
      1. Cash/sh = $1.81
    2. $AVIR – Aviragen Therapeutics Inc :
      1. Cash/sh = $0.95
    3. $CYCC – Cyclacel Pharmaceuticals Inc :
      1. Cash/sh = $1.93
    4. $EARS – Auris Medical Holding AG :
      1. Cash/sh = $1.12
    5. $ECYT – Endocyte, Inc. :
      1. Cash/sh = $2.85
    6. $EGLT – Egalet Corp :
      1. Cash/sh = $2.30
    7. $OPHT – Ophthotech Corp :
      1. Cash/sh = $5.44
    8. $ROKA – Roka Bioscience Inc :
      1. Cash/sh = $1.68

    Please also Share Your Favorite Stocks currently Trading Below Cash (TBC) here in this Topic as well, ok?

    #2549

    Michael DeVries
    Keymaster

    #Bullish #Stocks currently #TradingBelowBook (#TBB ) as of 09/01/2017 include:

    1. $ADHD – Alcobra Ltd :
      1. Book/sh = $1.71
    2. $CYCC – Cyclacel Pharmaceuticals Inc :
      1. Book/sh = $3.00
    3. $ECYT – Endocyte, Inc. :
      1. Book/sh = $2.73
    4. $LBIX – Leading Brands, Inc (USA) :
      1. Book/sh = $1.19
    5. $NVGN – Novogen Limited (ADR) :
      1. Book/sh = $22.22
    6. $ROKA – Roka Bioscience Inc :
      1. Book/sh = $2.44

    Please also Share Your Favorite Stocks currently Trading Below Book (TBB) here in this Topic as well, ok?

    #2645

    Michael DeVries
    Keymaster

    Bullish Stocks currently Trading Below Cash (TBC) as of 10/01/2017 include:

    1. $ADHD – Alcobra Ltd :
      1. Cash/sh = $1.81
    2. $AVIR – Aviragen Therapeutics Inc :
      1. Cash/sh = $1.00
    3. $EARS – Auris Medical Holding AG :
      1. Cash/sh = $1.12
    4. $ECYT – Endocyte, Inc. :
      1. Cash/sh = $2.80
    5. $LBIX – Leading Brands, Inc (USA) :
      1. Cash/sh = $0.98
    6. $OPHT – Ophthotech Corp :
      1. Cash/sh = $5.44
    7. $OREX – Orexigen Therapeutics, Inc. :
      1. Cash/sh = $5.69
    8. $ROKA – Roka Bioscience Inc :
      1. Cash/sh = $1.68
    9. $RTTR – Ritter Pharmaceuticals Inc :
      1. Cash/sh = $0.42
    10. $TNXP – Tonix Pharmaceuticals Holding Corp. :
      1. Cash/sh = $4.67

    Please also Share Your Favorite Stocks currently Trading Below Cash (TBC) here in this Topic as well, ok?

    #2678

    Michael DeVries
    Keymaster

    The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 10/09/2017 – 10/13/2017:

    1) ROSG – Rosetta Genomics Ltd. (USA)
    a. Buy at < ~ $0.98
    b. Sell at >~ $1.40
    c. Catalysts:
    1. The sale of PDx is expected to close within the next several weeks; 20170908; 20171231; https://finance.yahoo.com/news/rosetta-genomics-enters-agreement-sell-123000567.html

    2) ARTW – Arts-Way Manufacturing Co. Inc.
    a. Buy at < ~ $2.40
    b. Sell at >~ $3.50

    3) ONTX – Onconova Therapeutics Inc – Trading Below Cash
    a. Buy at < ~ $1.50
    b. Sell at >~ $1.99
    c. Catalysts:
    1. Phase 3 – Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine; 20171201; 20180531; https://ClinicalTrials.gov/show/NCT01928537
    2. Phase 3 enrolling. Interim analysis due 4Q 2017. Noted August 15, 2017 that enrollment has been slower than expected. – IV Rigosertib – INSPIRE – 2nd-line HR-MDS (high risk myelodysplastic syndromes) – Phase 3; 20171231; 20171231; http://investor.onconova.com/releasedetail.cfm?ReleaseID=1037302
    3. Phase 2 – Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs; 20171201; 20180531; https://ClinicalTrials.gov/show/NCT01904682
    4. Original Phase 3 trial did not meet endpoint in Feb 2014. However, following “subgroup analyses” and lack of current treatment options a further Phase 3 trial was initiated in December 2015. Interim analysis due 2H 2017. Enrollment to be completed 1Q 2018. – IV Rigosertib – INSPIRE – 2nd-line HR-MDS (high risk myelodysplastic syndromes) – Phase 3; 20170701; 20171231; https://www.sec.gov/Archives/edgar/data/1130598/000110465916156981/a16-17154_110q.htm
    5. Phase 3 – Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts; 20171201; 20180531; https://ClinicalTrials.gov/show/NCT01241500
    6. Phase 1Phase 2 – Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine; 20180601; 20181031; https://ClinicalTrials.gov/show/NCT01926587
    7. Phase 2 – Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia; 20220801; 20220831; https://ClinicalTrials.gov/show/NCT02730884
    8. Phase 3 – Controlled Study of Rigosertib Versus Physicians Choice of Treatment in MDS Patients After Failure of an HMA; 20180601; 20180930; https://ClinicalTrials.gov/show/NCT02562443
    9. Phase 1 – Three Dosing Schedules of Oral Rigosertib in MDS Patients; 20180401; 20181031; https://ClinicalTrials.gov/show/NCT02075034
    10. Phase 1 – Dose-escalation, Safety and Pharmacokinetic Study of Briciclib in Advanced Solid Tumors; 20180501; 20181231; https://ClinicalTrials.gov/show/NCT02168725

    4) EVAR – Lombard Medical Inc – Trading Below Cash
    a. Buy at < ~ $0.40
    b. Sell at >~ $0.50
    c. Catalysts:
    1. Phase 4 – AAA Registry: Clinical Outcomes of Highly Angulated anatomY Treated With the Aorfix™ Stent Graft; 20170401; 20220430; https://ClinicalTrials.gov/show/NCT02480595
    2. NA – Prospective Aneurysm Trial: High Angle Aorfix™ Bifurcated Stent Graft; 20110901; 20180131; https://ClinicalTrials.gov/show/NCT00522535
    3. NA – Treating Cognitive Deficits in Spinal Cord Injury; 20200131; 20200131; https://ClinicalTrials.gov/show/NCT03037879
    4. NA – Aorfix Intelliflex First in Human Study; 20171101; 20211130; https://ClinicalTrials.gov/show/NCT02907762

    What do you think about these Stock Picks to Buy at these Price Targets?

    What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 10/09/2017 – 10/13/2017, and Why?

    #2719

    Michael DeVries
    Keymaster

    The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 10/16/2017 – 10/20/2017:

    1) ONVO – Organovo Holdings Inc
    a. Buy at < ~ $1.60
    b. Sell at >~ $4.99
    c. Catalysts:
    1. Q2 2018 Organovo Holdings Inc Earnings Release (Estimated)
    -; 20171101; 20171101; https://www.google.com/finance?q=ONVO

    2) EGLT – Egalet Corp – Trading Below Cash
    a. Buy at < ~ $1.01
    b. Sell at >~ $1.59
    c. Catalysts:
    1. Phase 3 to be completed 4Q 2017. NDA planned for 2018. – Egalet-002 – Moderate to severe chronic pain – Phase 3; 20171001; 20171231; http://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=11315453&type=HTML&symbol=EGLT&companyName=Egalet+Corporation&formType=8-K&dateFiled=2017-01-09

    3) VVUS – VIVUS, Inc. – Trading Below Cash
    a. Buy at < ~ $0.86
    b. Sell at >~ $1.30
    c. Catalysts:
    1. Q3 2017 VIVUS Inc Earnings Release (Estimated)
    -; 20171107; 20171107; https://www.google.com/finance?q=VVUS
    2. Phase 2 – Qsymia as an Adjunct to Surgical Therapy in the Superobese; 20171201; 20171231; https://ClinicalTrials.gov/show/NCT02301416

    4) ROSG – Rosetta Genomics Ltd. (USA)
    a. Buy at < ~ $0.98
    b. Sell at >~ $1.40
    c. Catalysts:
    1. The sale of PDx is expected to close within the next several weeks; 20170908; 20171231; https://finance.yahoo.com/news/rosetta-genomics-enters-agreement-sell-123000567.html

    5) ARTW – Arts-Way Manufacturing Co. Inc.
    a. Buy at < ~ $2.40
    b. Sell at >~ $3.50

    6) EVAR – Lombard Medical Inc – Trading Below Cash
    a. Buy at < ~ $0.40
    b. Sell at >~ $0.50
    c. Catalysts:
    1. Phase 4 – AAA Registry: Clinical Outcomes of Highly Angulated anatomY Treated With the Aorfix™ Stent Graft; 20170401; 20220430; https://ClinicalTrials.gov/show/NCT02480595
    2. NA – Prospective Aneurysm Trial: High Angle Aorfix™ Bifurcated Stent Graft; 20110901; 20180131; https://ClinicalTrials.gov/show/NCT00522535
    3. NA – Treating Cognitive Deficits in Spinal Cord Injury; 20200131; 20200131; https://ClinicalTrials.gov/show/NCT03037879
    4. NA – Aorfix Intelliflex First in Human Study; 20171101; 20211130; https://ClinicalTrials.gov/show/NCT02907762

    What do you think about these Stock Picks to Buy at these Price Targets?

    What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 10/16/2017 – 10/20/2017, and Why?

    #2750

    Michael DeVries
    Keymaster

    The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 10/23/2017 – 10/27/2017:

    1) ARTW – Arts-Way Manufacturing Co. Inc.
    a. Buy at < ~ $2.40
    b. Sell at >~ $3.50

    2) ONVO – Organovo Holdings Inc
    a. Buy at < ~ $1.38
    b. Sell at >~ $1.80
    c. Catalysts:
    1. Q2 2018 Organovo Holdings Inc Earnings Release (Estimated)
    -; 20171101; 20171101; https://www.google.com/finance?q=ONVO

    3) EVAR – Lombard Medical Inc
    a. Buy at < ~ $0.40
    b. Sell at >~ $0.50
    c. Catalysts:
    1. Phase 4 – AAA Registry: Clinical Outcomes of Highly Angulated anatomY Treated With the Aorfix™ Stent Graft; 20170401; 20220430; https://ClinicalTrials.gov/show/NCT02480595
    2. NA – Prospective Aneurysm Trial: High Angle Aorfix™ Bifurcated Stent Graft; 20110901; 20180131; https://ClinicalTrials.gov/show/NCT00522535
    3. NA – Treating Cognitive Deficits in Spinal Cord Injury; 20200131; 20200131; https://ClinicalTrials.gov/show/NCT03037879
    4. NA – Aorfix Intelliflex First in Human Study; 20171101; 20211130; https://ClinicalTrials.gov/show/NCT02907762

    What do you think about these Stock Picks to Buy at these Price Targets?

    What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 10/23/2017 – 10/27/2017, and Why?

    #2751

    Michael DeVries
    Keymaster

    Bullish Stocks currently Trading Below Cash (TBC) as of 10/20/2017 include:

    1. $AVIR – Aviragen Therapeutics Inc :
      1. Cash/sh = $1.00
    2. $EGLT – Egalet Corp :
      1. Cash/sh = $2.03
    3. $OPHT – Ophthotech Corp :
      1. Cash/sh = $5.48
    4. $ROKA – Roka Bioscience Inc :
      1. Cash/sh = $2.84
    5. $TNDM – Tandem Diabetes Care Inc :
      1. Cash/sh = $3.54
    6. $VVUS – VIVUS, Inc. :
      1. Cash/sh = $2.39

    Please also Share Your Favorite Stocks currently Trading Below Cash (TBC) here in this Topic as well, ok?

    #2752

    Michael DeVries
    Keymaster

    #Bullish #Stocks currently #TradingBelowBook (#TBB ) as of 10/20/2017 include:

    1. $HEB – Hemispherx BioPharma, Inc :
      1. Book/sh = $0.51
    2. $MICT – Micronet Enertec Technologies Inc :
      1. Book/sh = $0.80
    3. $NVGN – Novogen Limited (ADR) :
      1. Book/sh = $21.86
    4. $ROKA – Roka Bioscience Inc :
      1. Book/sh = $5.93
    5. $ROSG – Rosetta Genomics Ltd. (USA) :
      1. Book/sh = $2.40

    Please also Share Your Favorite Stocks currently Trading Below Book (TBB) here in this Topic as well, ok?

    #2776

    Michael DeVries
    Keymaster

    The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 10/30/2017 – 11/03/2017:

    1) CEMP – Cempra Inc – Trading Below Cash
    a. Buy at < ~ $2.05
    b. Sell at >~ $3.50
    c. Catalysts:
    1. Phase 2Phase 3 – Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated; 20171001; 20181231; https://ClinicalTrials.gov/show/NCT02569541
    2. Phase 2/3 data due by the end of 2017. – Taksta – Fusidic acid – Refractory infections in bones and joints – Phase 2/3; 20171231; 20171231; http://investor.cempra.com/secfiling.cfm?filingid=1193125-17-252119&CIK=1461993
    3. Phase 2Phase 3 – Safety and Efficacy of Solithromycin in Adolescents and Children With Community-acquired Bacterial Pneumonia; 20181201; 20181231; https://ClinicalTrials.gov/show/NCT02605122

    2) EGLT – Egalet Corp – Trading Below Cash
    a. Buy at < ~ $0.97
    b. Sell at >~ $1.54
    c. Catalysts:
    1. Phase 3 to be completed 4Q 2017. NDA planned for 2018. – Egalet-002 – Moderate to severe chronic pain – Phase 3; 20171001; 20171231; http://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=11315453&type=HTML&symbol=EGLT&companyName=Egalet+Corporation&formType=8-K&dateFiled=2017-01-09

    3) ONVO – Organovo Holdings Inc
    a. Buy at < ~ $1.38
    b. Sell at >~ $1.80
    c. Catalysts:
    1. Q2 2018 Organovo Holdings Inc Earnings Release (Estimated)
    -; 20171101; 20171101; https://www.google.com/finance?q=ONVO

    What do you think about these Stock Picks to Buy at these Price Targets?

    What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 10/30/2017 – 11/03/2017, and Why?

    #2778

    Michael DeVries
    Keymaster

    #Bullish #Stocks currently #TradingBelowBook (#TBB ) as of 10/27/2017 include:

    1. $EVAR – Lombard Medical Inc :
      1. Book/sh = $0.89
    2. $HEB – Hemispherx BioPharma, Inc :
      1. Book/sh = $0.51
    3. $MICT – Micronet Enertec Technologies Inc :
      1. Book/sh = $0.80
    4. $NVGN – Novogen Limited (ADR) :
      1. Book/sh = $21.42
    5. $ROKA – Roka Bioscience Inc :
      1. Book/sh = $5.93
    6. $ROSG – Rosetta Genomics Ltd. (USA) :
      1. Book/sh = $2.40

    Please also Share Your Favorite Stocks currently Trading Below Book (TBB) here in this Topic as well, ok?

    #2833

    Michael DeVries
    Keymaster

    The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 11/13/2017 – 11/17/2017:

    1) PERI – Perion Network Ltd
    a. Buy at < ~ $0.94
    b. Sell at >~ $2.00

    2) GNCA – Genocea Biosciences Inc – Trading Below Cash
    a. Buy at < ~ $1.03
    b. Sell at >~ $2.00
    c. Catalysts:
    1. Phase 2 – Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection; 20180630; 20180630; https://ClinicalTrials.gov/show/NCT03146403
    2. NA – Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity; 20181201; 20181231; https://ClinicalTrials.gov/show/NCT02910284

    3) ABIL – Ability Inc
    a. Buy at < ~ $0.57
    b. Sell at >~ $1.00

    4) VICL – Vical Incorporated – Trading Below Cash
    a. Buy at < ~ $1.66
    b. Sell at >~ $2.70
    c. Catalysts:
    1. Initiated Phase 3 Jun 2013. Enrollment due to be completed 3Q 2016. Topline data due 1Q2018. – ASP0113 Vaccine – Hematopoietic cell transplant recipients – Phase 3; 20180101; 20180331; http://www.vical.com/investors/news-releases/News-Release-Details/2016/Vical-Reports-Third-Quarter-2016-Financial-Results/default.aspx
    2. Phase 3 trial completion announced November 10, 2017. Top-line data due 1Q 2018. – ASP0113 Vaccine – Hematopoietic cell transplant recipients – Phase 3; 20180331; 20180331; http://www.vical.com/investors/news-releases/News-Release-Details/2017/Vical-Reports-Third-Quarter-2017-Financial-and-Operational-Results/default.aspx
    3. Phase 2 trial initiated September 2016. Enrollment completion announced April 19, 2017 with data due 2Q 2018. – VCL-HB01 HSV-2 Therapeutic Vaccine – Genital Herpes in Adults – Phase 2; 20180630; 20180630; http://www.vical.com/investors/news-releases/News-Release-Details/2017/Vical-Reports-Third-Quarter-2017-Financial-and-Operational-Results/default.aspx

    5) TISA – Top Image Systems Ltd.
    a. Buy at < ~ $1.10
    b. Sell at >~ $1.75

    6) XENE – Xenon Pharmaceuticals Inc – Trading Below Cash
    a. Buy at < ~ $2.25
    b. Sell at >~ $3.00
    c. Catalysts:
    1. NA – Xenon-129 Magnetic Resonance Imaging of Healthy Subjects: Hardware and Software Development and Reproducibility; 20180801; 20180831; https://ClinicalTrials.gov/show/NCT02484885
    2. NA – Cerebral and Spinal Protection of Xenon Post-conditioning in Patients Undergoing Aortic Dissection Repair; 20180701; 20180930; https://ClinicalTrials.gov/show/NCT02774096
    3. NA – Hyperpolarized Xenon Imaging in Patients With Cystic Fibrosis; 20181001; 20181031; https://ClinicalTrials.gov/show/NCT02912637
    4. Phase 1Phase 2 – Hyper Polarized Xenon-129 MRI vs Xenon-133 Scintigraphy; 20181231; 20191231; https://ClinicalTrials.gov/show/NCT03331302
    5. Phase 3 – A Comparison of Technegas and Xenon-133 Planar Lung Imaging in Subjects Referred for Ventilation Scintigraphy; 20181201; 20190531; https://ClinicalTrials.gov/show/NCT03054870
    6. Early Phase 1 – New Technology to Assess Treatment for Chronic Obstructive Pulmonary Disease (COPD); 20180601; 20180630; https://ClinicalTrials.gov/show/NCT02826343
    7. NA – Xenon Against Postoperative Oxygen Impairment; 20170701; 20171231; https://ClinicalTrials.gov/show/NCT02468531
    8. Genentech anticipates initiating a Phase 2 clinical trial in 2017 for the potential treatment of pain; 20170101; 20171231; http://investor.xenon-pharma.com/phoenix.zhtml?c=253202&p=irol-newsArticle&ID=2234828
    9. Xenon expects to file an investigational new drug (IND) application in the fourth quarter of 2017; 20171001; 20171231; http://investor.xenon-pharma.com/phoenix.zhtml?c=253202&p=irol-newsArticle&ID=2234828
    10. Phase 1Phase 2 – Use of Hyperpolarized 129Xe MR Lung Imaging in Adults for Calibration; 20180201; 20190228; https://ClinicalTrials.gov/show/NCT02316379
    11. Phase 1Phase 2 – Use of Hyperpolarized Xenon Gas for Lung Imaging in Children and Adults; 20171101; 20181130; https://ClinicalTrials.gov/show/NCT02272049
    12. Phase 1 – Using MRI to Visualize Regional Therapy Response in Idiopathic Pulmonary Fibrosis; 20190401; 20190430; https://ClinicalTrials.gov/show/NCT02478268
    13. NA – A Single-Centre Pilot Study Exploring the Utility of Magnetic Resonance Imaging in Patients With Chronic Lung Disease; 20201001; 20201031; https://ClinicalTrials.gov/show/NCT02723474
    14. Phase 1 – Hyperpolarized Xenon-129 Magnetic Resonance Imaging and Spectroscopy of Brown Fat: Healthy Adult Volunteer Pilot Study; 20200901; 20200930; https://ClinicalTrials.gov/show/NCT02220426
    15. Phase 1 – Hyperpolarized 129Xe MRI for Imaging Pulmonary Function; 20201201; 20211231; https://ClinicalTrials.gov/show/NCT01280994
    16. NA – Monitoring Response to Orkambi in Cystic Fibrosis Lung Disease by Inhaled Xenon MRI; 20210801; 20211231; https://ClinicalTrials.gov/show/NCT02848560
    17. Phase 2 – Hyperpolarized Xenon-129 MRI: a New Multi-dimensional Biomarker to Determine Pulmonary Physiologic Responses to COPD Therapeutics; 20201231; 20220131; https://ClinicalTrials.gov/show/NCT03002389
    18. NA – 129 Xenon MRI in Chronic Lung Disease; 20200801; 20200831; https://ClinicalTrials.gov/show/NCT02723500
    19. Early Phase 1 – HP Xenon-129 fMRI of Healthy Volunteers and Participants With Alzheimers Disease; 20190601; 20190630; https://ClinicalTrials.gov/show/NCT02638519
    20. Phase 2 – A Test of Neural Inertia in Humans With Xenon; 20190401; 20190831; https://ClinicalTrials.gov/show/NCT02768727
    21. Phase 2 – Xenon-129 Lung Magnetic Resonance Imaging: Study of Healthy Volunteers and Participants With Pulmonary Disease; 20190801; 20190831; https://ClinicalTrials.gov/show/NCT02740868
    22. Phase 2 – Xenon and Cooling Therapy in Babies at High Risk of Brain Injury Following Poor Condition at Birth; 20190831; 20190831; https://ClinicalTrials.gov/show/NCT02071394
    23. Phase 1 – Longitudinal MR Imaging of Pulmonary Function in Patients Receiving Thoracic Radiation Treatment; 20190801; 20190831; https://ClinicalTrials.gov/show/NCT02478255

    7) PRSS – CafePress Inc
    a. Buy at < ~ $1.67
    b. Sell at >~ $2.20

    8) OASM – Oasmia Pharmaceutical AB – American Depositary Shares
    a. Buy at < ~ $0.80
    b. Sell at >~ $1.05
    c. Catalysts:
    1. 1. Doxophos appr. Russia. 2. Apealea appr. Europe (ovarian cancer & metastatic breast cancer) 3. Comm. agreement Apealea 4. Positive cash flow 5. Several license agreements of nano technology XR17 (similar to Celator) and lots more to come; 20170101; 20171231; https://stocktwits.com/swedetrader/message/76192391
    2. Q2 2018 Oasmia Pharmaceutical AB Earnings Release (Estimated); 20171130; 20171130; https://www.google.com/finance?q=OASM

    9) ONVO – Organovo Holdings Inc
    a. Buy at < ~ $1.38
    b. Sell at >~ $1.80

    What do you think about these Stock Picks to Buy at these Price Targets?

    What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 11/13/2017 – 11/17/2017, and Why?

Viewing 25 posts - 26 through 50 (of 56 total)

You must be logged in to reply to this topic.